Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Adding lumateperone to antidepressants improves sexual function in MDD patients. A phase 3 trial post hoc analysis found that after just 6 weeks, patients on adjunctive lumateperone 42 mg reported significantly better sexual functioning compared to placebo — with the benefit most pronounced in women. Roughly two-thirds of the improvement appears to be driven by better depression control itself.
Sexual dysfunction affects an estimated 68% of people with major depressive disorder (MDD) — and it's one of the top reasons patients stop taking their antidepressants. A new post hoc analysis published in The Journal of Clinical Psychiatry offers some encouraging news: adding lumateperone (Caplyta) 42 mg to existing antidepressant therapy significantly improved sexual functioning after just 6 weeks, compared to placebo.
The analysis drew from a phase 3, double-blind randomized controlled trial of treatment-resistant MDD patients. Both men and women saw improvements in pleasure and arousal, though the gains were only clinically meaningful in women. Importantly, patients who had no sexual dysfunction at baseline saw no worsening — suggesting lumateperone doesn't introduce new sexual side effects.
By the Numbers:
Why it matters: Sexual dysfunction is underreported in MDD and often worsens with standard treatments, pushing patients to quit therapy. Lumateperone's profile — improving depression and sexual function — could make it a valuable option for patients who've struggled with this common but rarely discussed side effect.
